Literature DB >> 24919150

Cancer: natural-born killers unleashed.

Emilio Hirsch1, Francesco Novelli2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24919150     DOI： 10.1038/nature13503

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 3.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

Review 4.  PI3K in cancer-stroma interactions: bad in seed and ugly in soil.

Authors:  E Hirsch; E Ciraolo; I Franco; A Ghigo; M Martini
Journal:  Oncogene       Date:  2013-07-29       Impact factor: 9.867

5.  Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

Authors:  David A Fruman; Lewis C Cantley
Journal:  N Engl J Med       Date:  2014-03-13       Impact factor: 91.245

6.  PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.

Authors:  Eva Maria Putz; Michaela Prchal-Murphy; Olivia Annabella Simma; Florian Forster; Xaver Koenig; Hannes Stockinger; Roland P Piekorz; Michael Freissmuth; Mathias Müller; Veronika Sexl; Eva Zebedin-Brandl
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

Review 7.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

8.  Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Authors:  Dalya R Soond; Roberto Pineiro; Khaled Ali; Thorsten Hagemann; Wayne Pearce; Ee Lyn Lim; Hicham Bouabe; Cheryl L Scudamore; Timothy Hancox; Heather Maecker; Lori Friedman; Martin Turner; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962
  8 in total
  2 in total

Review 1.  Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners.

Authors:  Paola Cappello; Claudia Curcio; Giorgia Mandili; Cecilia Roux; Sara Bulfamante; Francesco Novelli
Journal:  Cancers (Basel)       Date:  2018-02-16       Impact factor: 6.639

Review 2.  A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.

Authors:  Qiong Xiang; Shuai Dong; Xian-Hui Li
Journal:  Med Sci Monit       Date:  2021-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.